Akari Therapeutics (AKTX) Q1 2026 earnings summary

Executive summary

• Focused on advancing lead ADC program AKTX-101 through IND-enabling activities and clinical readiness, with a projected Phase 1 trial by mid-2027.

• No commercial products or revenue; operations funded primarily through equity and convertible notes.

• Recent developments include initiation of GMP manufacturing for AKTX-101 and positive preclinical data presented at ASCO 2026.

Financial highlights

• Net loss for Q1 2026 was $14.5 million, up from $3.7 million in Q1 2025, mainly due to $12.1 million in non-cash impairment charges.

• Operating expenses rose to $15.8 million from $3.5 million year-over-year, driven by impairment of goodwill and IPR&D assets.

• Cash and restricted cash at March 31, 2026, totaled $2.8 million; accumulated deficit reached $279.0 million.

Outlook and guidance

• Existing cash is sufficient to fund operations into June 2026; additional capital will be required to continue operations beyond that point.

• Management is pursuing various funding strategies, including equity, debt, and strategic collaborations.

• Substantial doubt exists regarding ability to continue as a going concern within one year of the report date.